Cholestatic liver diseases: new targets, new therapies.

23 , 24 Subsequently, a randomized placebo-controlled study of 219 patients compared medium doses of UDCA (17–23 mg/kg/day) versus placebo for 5 years and showed a trend toward improved survival among UDCA-treated patients. 25 However, doses of 28–30 mg/kg/day were clearly associated with more frequent serious adverse events: patients receiving higher doses of UDCA were more likely to reach an endpoint, including cirrhosis, esophageal varices, cholangiocarcinom

also in 53,322 other papers

Interestingly, a recent pilot study of ATRA combined with moderate-dose UDCA was performed in PSC patients and showed improvement in ALT and complement-4 levels, but unfortunately its effect on ALP did not reach statistical significance. 39 Fibroblast growth factor 19 mimetics As mentioned, one of the many downstream effects of FXR activation is increased gene transcription of FGF 19, an enteral hormone known to repress bile acid synthesis via downregulation of CYP7A1. 1 , 34 FGF 19’s anticholestatic benefit may be limited by

also in 111,027 other papers